Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Novartis Pharmaceuticals. KISQALI® (ribociclib) tablets, for oral use: US prescribing Information. 2017. https://www.fda.gov . Accessed 31 Mar 2017.
2. Caldon CE, Daly RJ, Sutherland RL, et al. Cell cycle control in breast cancer cells. J Cell Biochem. 2006;97(2):261–74.
3. Network Cancer Genome Atlas. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
4. Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol. 2013;10(4):191–210.
5. Novartis. Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2− advanced breast cancer [media release]. 03 Aug 2016. http://www.novartis.com .
Cited by
67 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献